Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 5/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.32 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.32 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.32 |
| ▸ | EED | O75530 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31435911 | 0.93 | JAK2 (0.35) | METHTR6AXLCCNE1CDK2 | |
| SCHEMBL31436018 | 0.92 | CHRM3 (0.34) | METHTR6AXLCCNE1CDK2 | |
| SCHEMBL31435900 | 0.91 | MAP4K3 (0.41) | METHTR6MAP4K3 | |
| SCHEMBL31435980 | 0.84 | MAP4K3 (0.38) | METHTR6MAP4K3 | |
| SCHEMBL31435972 | 0.84 | ELANE (0.32) | AXLACVR1MTOR | |
| SCHEMBL31436005 | 0.83 | MAP4K3 (0.37) | METHTR6MAP4K3MTOR | |
| SCHEMBL31435914 | 0.82 | TNF (0.35) | METHTR6MTOR | |
| SCHEMBL31435973 | 0.82 | CYP3A4 (0.35) | METHTR6AXLACVR1CHRM3 | |
| SCHEMBL31435925 | 0.80 | KCNH2 (0.38) | AXLACVR1MTOR | |
| SCHEMBL31396578 | 0.77 | PTGDR2 (0.37) | HTR6PCSK9EED |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2025-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | TYRO3, TH, TYR | MET 1081/4885HTR6 1132/4885AXL 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.